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Abstract
Introduction: Limited evidence is available about the effectiveness of strategies to remind 
caregivers when to bring children back for future vaccinations in low- and middle-income country 
settings. We evaluated the effectiveness of two reminder strategies based on home-based 
vaccination records (HBR) in Indonesia.
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Methods: In this cluster-randomized controlled trial involving 3616 children <1 year of age, 90 
health facilities were randomly assigned to either a control group or one of two intervention 
groups: (1) HBR-only group, where healthcare workers provided an HBR to any child without an 
HBR during a vaccination visit and instructed the caregiver to keep it at home between visits, or 
(2) HBR + sticker group, where, in addition to HBR provision, healthcare workers placed 
vaccination appointment reminder stickers on the HBR. The primary outcome was receipt of the 
third dose of diphtheria-tetanus-pertussis-containing vaccine (DTPcv3) within 7 months and the 
secondary outcome was receipt of a timely DTPcv3 dose.
Results: Control group DTPcv3 coverage was 81%. In intention-to-treat analysis, neither 
intervention group had significantly different DTPcv3 coverage compared with the control group 
(RR = 0.94, 95% confidence interval [CI] 0.87; 1.02 for HBR-only group; RR = 0.97, 95% CI 
0.90; 1.04 for HBR + sticker group) by study end. However, children in the HBR + sticker group 
were 50% more likely to have received a DTPcv3 vaccination (RR = 1.46, 95% CI 1.02, 2.09) 
within 60 days of DTPcv1 vaccination, compared with children in the control group; children in 
the HBR-only group were not more likely to have done so (RR = 1.05, 95% CI 0.71, 1.55).
Discussion: Reminder stickers had an immediate effect on coverage by improving the 
proportion of children who received a timely DTPcv3 dose but no effect on the proportion who 
received DTPcv3 after 7 months. Coupling reminder stickers with strategies to address other 
reasons why children do not return for vaccination visits should be further explored.
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1. Introduction
The World Health Organization (WHO) recommends more than 10 vaccinations through 
early childhood to ensure protection against multiple diseases. WHO also recommends 
timely receipt of these vaccinations to ensure optimal protection [1]. A variety of 
interventions are available to remind parents to ensure they bring their child back to a health 
facility for all recommended vaccinations. These interventions are commonly described as 
parental reminder/recall systems, and they are used to remind a target population that 
vaccinations are due (reminders) or late (recall); these interventions are considered a key 
vaccine utilization tool available to healthcare providers [2]. Parental reminders can include 
letters or postcards to patients, person-to-person telephone calls, computerized telephone 
messages, combinations of postcards and telephone messages, community outreach, or 
reminders for healthcare providers alongside parents. Evaluations of parental reminders 
show a positive effect on vaccination uptake, with systematic reviews indicating that they 
can increase vaccination coverage by 4–20% [2–5]; however, nearly all studies described in 
these reviews were set in high-income countries.
In the 2015 systematic review of parental reminder studies, Harvey et al. identified 13 
randomized controlled trials (RCTs) of parental reminders; 11 used postal-based reminders 
and 2 used telephone reminders [3]. The majority of the reviewed studies were based in the 
United States; two were based in Pakistan, a lower-middle–income country [3,6,7]. The 
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Pakistan-based studies assessed the feasibility of using a future vaccination appointment 
date sticker on the child’s home-based record (HBR) or vaccination card and found that this 
strategy improved coverage of the third dose of diphtheria-pertussis-tetanus (DTPcv3) 
vaccine by 10–20%. Although these studies showed promising results, they were both of 
short duration (3 months), and the interventions were implemented by study personnel rather 
than healthcare providers. As highlighted by the systematic reviews and the two Pakistani 
studies, additional evaluation of HBR-based parental reminder strategies is needed in other 
low- and middle-income country settings to help researchers better understand their possible 
benefits.
WHO has long recommended that, globally, all children should receive an HBR (paper or 
electronic) to ensure that the caregiver is aware of the vaccination services the child has and 
has not received, to support health workers’ ability to determine vaccination status, and to 
empower caregivers in the care of the child; consequently, their recommended use is 
ubiquitous worldwide [8]. Placing a parental appointment sticker on the HBR could be a 
simple strategy for ensuring that parents return promptly for the next recommended 
childhood vaccination. Yet, in some countries, the proportion of caregivers who receive, 
maintain, or are allowed to keep the child’s home-based record at home can be quite low, 
which may limit the opportunity to use them as a means of providing parental reminders of 
future vaccinations. In Indonesia, for instance, a 2012 survey showed that only 41% of 
children aged 12–23 months had an HBR present during the household-based interview, 
even though 71% of parents indicated their child had received at least one recommended 
vaccination and that they knew the Indonesia government recommends that every child 
should have an HBR [9,10]. In Indonesia, a high proportion of children (97% in 2012) in 
Indonesia received the first dose of DTPcv, however, a substantial proportion of children 
(15%) dropped out by the third DTPcv dose, resulting in Indonesia having the fourth highest 
number of children (one million) globally who failed to complete the 3-dose DTPcv series.
Since little evidence exists about the effectiveness of vaccination reminders placed on a 
child’s HBR in low- and middle-income countries despite their promise shown in several 
high-income countries, the authors implemented a cluster-randomized control trial in 
Indonesia designed to estimate the effect of low-cost parental reminder interventions using 
HBRs on completion and timeliness of the 3-dose DTPcv series.
2. Methods
2.1. Study design, recruitment, and randomization
A cluster-randomized controlled trial (cRCT) design was used to measure the effect of each 
intervention, randomizing at the health facility level into one of three study groups. West 
Java province was selected because it has the largest population in Indonesia. Five districts 
in Indonesia’s West Java province (Cianjur, Cirebon, Kota Bundung, Kota Depok, and 
Sukabumi) were purposively chosen using the following criteria: (1) no known or 
anticipated activities were ongoing in the district to improve vaccination service utilization, 
(2) no communications messages were scheduled to promote home-based record ownership, 
and (3) they had a sufficiently large estimated target population to support study sample size 
requirements. The study intervention period began on January 1, 2016, and lasted 7 months.
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All public health facilities that provided vaccinations in these districts were included in the 
study sampling frame. Facility eligibility criteria included being government-owned 
(public), routine provision of vaccination services, and having an estimated number of 
annual births ≥360; the latter was used to aim to have at least 30 children, on average, attend 
for DTPcv1 vaccination in a single month. The initial sampling frame contained 264 public 
health facilities; two were omitted because they had no information on the number of annual 
births, and 32 were omitted because they had <360 annual births. To reduce possible 
confounding by district, the facility sampling frame was first stratified by district; then, 
within each district, six facilities were randomized to each study group using simple random 
sampling, for a total of 30 randomized facilities per group.
All children who received DTPcv1 in a study health facility in January 2016 and had the 
vaccination recorded on the facility vaccination register were eligible for inclusion in the 
study. The district health management teams and facility officer-in-charge gave consent for 
participation in the study prior to randomization. This study was approved by the 
institutional review boards of the University of Indonesia and US Centers for Disease 
Control and Prevention (CDC).
2.2. Study groups and intervention procedures
The three study groups consisted of two intervention arms (HBR-only and HBR + sticker) 
and one control arm. In HBR-only study group health facilities, healthcare providers were 
instructed to provide an HBR to a caregiver of a child any time the caregiver had not yet 
received an HBR or had forgotten to bring the HBR to the vaccination visit. If the HBR was 
a replacement, the provider was to update the replacement HBR with information from the 
vaccination register. The provider was instructed to tell the parent to keep the HBR at home 
and to remember to bring it back at the next vaccination visit.
In the HBR + sticker intervention health facilities, healthcare providers followed the same 
HBR provision rules as those in the HBR-only study group, but also affixed a future 
vaccination visit reminder sticker to the front of the home-based record for children still due 
for a future vaccination, wrote the date of the next vaccination visit on the reminder sticker, 
and explained the purpose of the sticker to the caregiver. The sticker was bright yellow, 
approximately 50 mm in width and 12 mm in height, and had a back adhesive that was 
removed when the provider applied the sticker to the HBR. All children coming for 
vaccination were eligible for this intervention. In control study group health facilities, 
healthcare providers followed their usual practice for vaccination reminders, home-based 
record provision, and home-based record storage location. Indonesia immunization training 
guidelines instruct healthcare providers in Indonesia to simply ensure that caregivers are 
aware they should return for future vaccinations, but little information about how to ensure 
their awareness is systematically provided.
For healthcare provider orientation to the interventions and provision of intervention 
materials, a cascading approach that would mimic how Indonesia introduces a new health 
intervention was used so that our study outcome measurements would best reflect 
intervention effectiveness. The cascade approach started with an orientation for national, 
province, and district health management staff and partner organizations (UNICEF and 
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CDC) in October 2015. After this orientation, the province and district health teams were 
instructed to orient intervention health facilities and provide intervention materials prior to 
January 2016.
2.3. Outcomes
The primary outcome of interest was for children to receive DTPcv3 before the end of the 
study. Vaccination status was determined by retrospective review of the health facility 
vaccination register. At study end, trained data collectors visited each study facility and 
abstracted the complete vaccination record for each child that had received DTPcv1 in 
January 2016. Information abstracted on each child included gender, date of birth, and 
notation of all vaccinations received.
Two methods were used to calculate the secondary outcome of interest, timeliness of a 
DTPcv3 vaccination: (1) receipt of DTPcv3 within a certain time period after DTPcv1 to 
reflect adherence to their future vaccination appointment date, and (2) time to DTPcv3 
vaccination or end of intervention period. For the first method, a binary variable was created 
for each child that indicated receipt of DTPcv3 56–60 days after receiving DTPcv1 because 
56 days is the minimum recommended spacing between these doses. Additional binary 
variables indicating receipt of valid DTPcv3 within 70 days of DTPcv1 and within 90 days 
of DTPcv1 were also created. For the second method, a variable defined as the number of 
days between DTPcv1 vaccination and either DTPcv3 vaccination (event) or end of study 
(censoring) was created. The latter variable was used in survival analyses.
2.4. Statistical analysis
The following assumptions were made to calculate the a-priori sample size: (a) 70% 
DTPcv3 coverage in control groups, based on 2014 coverage information in study districts; 
(b) 40 children per facility, based on average target population of children <1 year of age; (c) 
intraclass correlation coefficient of 0.10, based on recent household surveys; (d) alpha of 
0.05; and (e) power of 80% to detect an absolute increase of 11% in the proportion of 
children receiving DTPcv3 in the intervention versus control study groups (based on results 
from previous reminder studies showing 10–35% coverage increase) [2,3]. The target sample 
size was 30 facilities per group, yielding a total target sample of 1200 children in each study 
group.
Before being analyzed, the dataset was examined for any invalid or missing dates of birth, 
invalid dates of DTPcv vaccination, and invalid doses. Invalid dates of birth and vaccination 
were identified by examining if any dates of DTPcv vaccination came before the dates of 
birth; those that occurred were reconciled if feasible, and those that could not be reconciled 
were excluded. Invalid doses were defined as those with a minimum interval between 
DTPcv doses of <28 days. For all analyses, only valid DTPcv dose data were used.
2.5. Intention-to-treat analysis
Our primary analyses were intent to treat (ITT), with individuals analyzed according to the 
group with which their facility was randomized. We modeled binary and continuous 
outcomes using generalized estimating equations (GEE) with a log link function to calculate 
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risk differences and risk ratios with 95% confidence intervals (CI). A cluster effect for 
facility, with an exchangeable correlation structure, was included in the model. Covariates 
used in the model were child’s sex (male/female), age of child at DTPcv1 vaccination date 
(in days), hepatitis B birth dose vaccination status prior to receipt of DTPcv1 (yes/no), and 
child’s home district.
We conducted a survival analysis by modeling time to DTPcv3 vaccination using a Cox 
proportional hazards model to calculate hazard ratios with 95% CI. A cluster effect for 
facility was included in the model alongside previous covariates. The calculation of survival 
time started at the day of DTPcv1 and ended the day of DTPcv3 vaccination or end of study 
period. SAS version 9.3 and SAS-callable SUDAAN were used for analysis of data.
2.6. Per-protocol analysis and health worker survey
To assess adherence to the intervention, staff members at every intervention health facility 
were interviewed at the end of the study to provide information on which month they 
received intervention materials (reminder stickers and additional home-based records) and 
their acceptance and use of the interventions. All health workers who were involved in 
administering vaccinations at the facility were included in these interviews conducted by 
trained data collectors. A-priori, a decision was made that if intervention materials had 
arrived after the start of the intervention period, a per-protocol analysis would be conducted 
whereby intervention facilities would be reclassified into the appropriate study group and the 
various analyses redone per the previous methods.
2.7. Post-hoc analyses
In a post-hoc analysis, the researchers re-analyzed their primary and secondary outcomes of 
interest using ITT among only those children who had received a second dose of DTPcv 
(DTPcv2), under the theories that intervention facility healthcare providers would be more 
experienced with implementing the interventions by the DTPcv2 visit and thus would adhere 
better to the intervention protocols. Additionally, since a number of healthcare providers in 
the intervention groups failed to receive intervention materials in the first month of the 
intervention but did receive them in the second month of the intervention, a higher overall 
proportion of the intervention facilities would be implementing the intervention protocol by 
the time of the DTPcv2 visit.
3. Results
Of the 3633 child immunization records abstracted from health facilities, 17 were discarded 
(12 from Group 1 facilities and 5 from Group 2 facilities) because they had invalid 
vaccination data. Vaccination records from 3616 children in 90 health facilities were 
analyzed (Fig. 1). Most baseline indicators were similar across study groups; however, 
children in the HBR-only study group were generally older at time of Penta1 vaccination (88 
days of age versus 77–79 days) and less likely to have received Bacillus Calmette–Guérin 
(BCG) vaccination (90% versus 95%) at baseline compared with children in the other two 
groups (Table 1).
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During the 60 (response rate = 100%) healthcare provider surveys, 21 intervention providers 
indicated receipt of intervention materials (cards and/or stickers) after the presumed start of 
the intervention on 1 January. Therefore, for the per protocol analyses only, we reclassified 
facilities based on whether or not they had received intervention materials before January 
and reanalyzed the results per protocol. Among the 30 HBR + sticker intervention facilities, 
7 were reclassified as HBR-only and 3 were reclassified as control for purposes of the per 
protocol analysis. Among those 10 that received intervention materials after the start of the 
intervention period on 1-January-2016, 9 had received the materials to initiate the 
intervention as of 1-Feburary-2016 and 1 received the materials to initiate by 1-May-2016. 
Among the 30 HBR-only facilities, 11 were reclassified as control for the per protocol 
analysis; among these 11 who received intervention materials late, 7 had received them as of 
1-Feburary-2016, 1 as of 1-March −2016 and 3 as of 1-April-2016.
3.1. Primary outcome
Under ITT analysis, by the end of the 200-day study period, no significant difference was 
noted in the proportion of HBR + sticker group children who had received DTPcv3 
vaccination (77%) compared with the control group (81%) (RR = 0.97, 95% CI:0.90, 1.04), 
nor in the proportion of HBR-only group children who had received DTPcv3 (74%) 
compared with those in the control group (RR = 0.94, 95% CI:0.87, 1.02) (Table 2).
Under per protocol analysis, no significant difference was found in the proportion of HBR + 
sticker group children who had received DTPcv3 vaccination (77%) compared with children 
in the control group (78%) (RR = 0.99, 95% CI: 0.98, 1.09), nor in the proportion of HBR-
only group children who had received DTPcv3 (74%) compared with those in the control 
group (RR = 0.96, 95% CI: 0.88,1.05) (Table 3). Using a modified per protocol analysis 
approach where intervention facilities were not reclassified into the control group if they had 
not received any intervention materials by January 2016, but instead these facilities were 
dropped from the analysis, the results were virtually the same as in the intention-to-treat 
analysis.
3.2. Secondary outcomes
Under ITT analysis, children in the HBR + sticker group were nearly 50% more likely to 
have received a valid DTPcv3 vaccination within 60 days of DTPcv1 vaccination (DTPcv3 
coverage at 60 days = 32%) compared with children in the control group (23%); (RR = 1.46, 
95% CI: 1.02, 2.09) (Table 2). Children in the HBR-only group were 5% more likely to have 
done so when compared with those in the control group, although this difference was not 
significant (DTPcv3 coverage at 60 days = 24%), (RR = 1.05, 95%CI:0.71, 1.55) (Fig. 2). 
By 90 days after DTPcv1 vaccination, the likelihood of DTPcv3 vaccination in the HBR + 
sticker group compared with control group children was equal (61%), (RR = 0.99, 95% CI:
0.96, 1.03) (Table 2, Fig. 2). Survival analysis results indicated similar trends; HBR + sticker 
group children had a 9% greater likelihood of time to DTPcv3 vaccination within 60 days of 
DTPcv1 (HR: 1.09, 95% CI: 0.96, 1.22) compared with control group children, whereas 
there was no difference in time to DTPcv3 vaccination within 60 days between HBR-only 
children and control group children (HR: 0.99, 95% CI: 0.89, 1.09).
Wallace et al. Page 7
Vaccine. Author manuscript; available in PMC 2020 October 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Compared with ITT results, under per protocol analysis the HBR + sticker intervention 
showed a significant and stronger effect on the proportion of children in the HBR-only 
group who received a more timely DTPcv3 vaccination compared with control group 
children (Table 3). In total, 13% (95% CI: 2%, 24%) more children in the HBR + sticker 
group received DTPcv3 within 60 days of DTPcv1 (coverage = 37%) compared with control 
group children (coverage = 24%) and 10% (95%CI: 1%, 22%) more within 70 days (57% 
versus 47%) (Fig. 3). By 100 days, the proportion was equal (69%) (RD: 0%, 95% CI: 
[C0]9%, 8%) between these groups, again indicating a transient timeliness effect from the 
HBR + sticker intervention. Survival analysis results indicated timeliness effects that were 
also stronger compared with ITT results. HBR + sticker group children were 23% more 
likely to have received a more timely DTPcv3 vaccination within the 200-day follow-up 
period compared with control group children (HR: 1.23, 95% CI: 1.11, 1.37). Per protocol 
survival analysis indicated HBR-only group children were 11% more likely to have received 
a more timely DTPcv3 vaccination compared with control group children (HR: 1.11, 95% 
CI: 1.02,1.22).
In a post-hoc analysis among only children who received DTPcv2 (n = 3088, 85% of total), 
children in the HBR + sticker group were significantly more likely to have received a more 
timely DTPcv3 vaccination (within 30 days of DTPcv2) than control group children (RR: 
1.61, 95% CI: 1.23, 2.10); children in the HBR-only group were also more likely to have 
received a more timely DTPcv3 vaccination but this as not statistically significant (RR: 1.12, 
95% CI:0.82, 1.53) (Table 3). By the end of the 200-day study period, children across all 
three study groups were nearly equally likely to have received DTPcv3 vaccination (RR for 
HBR + sticker group:1.03, 95% CI: 0.98, 1.07; RR for HBR-only group: 0.99, 95% CI:0.93, 
1.04).
3.3. Healthcare provider acceptability
During post-intervention healthcare provider surveys in each of the two intervention groups 
(30 providers in each group), 100% of the 60 providers in both groups indicated they allow 
caregivers to keep the HBR at home between healthcare visits. When asked how they 
communicate to caregivers about when to come back for the next childhood vaccination 
visit, most HBR + sticker group providers used the sticker (90%) and a verbal reminder 
(86%); smaller numbers used an additional written reminder or additional note on the card 
alongside the use of the sticker (33%). Among HBR-only providers, 80% used a verbal 
reminder and 47% used a written reminder or a note on the card. All (100%) providers in 
both the HBR-only group and the HBR + sticker group were supportive of using reminder 
stickers on the HBR because they believed it helped remind the parent of future vaccination 
visits. Providers reported that the yellow color of the sticker contrasted well with the HBR, 
so it drew the attention of the caregiver and the placement of the sticker on the front of the 
HBR meant that the caregiver did not have to open the book to see the next date of 
vaccination. In the HBR + sticker group, 100% of providers were also supportive of 
continuing to use the reminder stickers, although 17% indicated some problems with using 
them. The main problem reported was that the providers sometimes found that the sticker 
backing was difficult to remove.
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The providers in both intervention groups also provided feedback specific to the HBR 
component of the intervention. In the post-intervention survey, only 60% of providers in 
both groups indicated they always provided a replacement HBR to those who came without 
an HBR (and had received one previously), and about 40% and 30% of HBR + sticker and 
HBR-only providers, respectively, indicated they supported the continued policy of 
providing a replacement HBR. When further queried about this feedback, providers reported 
that having to fill in a replacement HBR was a “nuisance”; others suggested providing a 
small card as a substitute until the parent returned with the old HBR. Multiple providers also 
indicated that if the distance was not far, they sent parents back home to retrieve the 
forgotten HBR rather than issuing a replacement HBR.
4. Discussion
Children who attended facilities that provided sticker-based reminders of future vaccination 
appointments were more likely to receive timely DTPcv3 vaccination compared with 
children in the control group; therefore, children in these groups were vulnerable to the 
diseases these vaccines protected against for shorter periods during their first year of life. 
However, the positive effect on timeliness of vaccination did not translate into overall higher 
DTPcv3 coverage by the end of the 7-month study period compared with coverage in the 
control group. In our primary analysis, providing a new home-based record to parents of 
children who came without one did not have any effects on vaccination coverage or 
timeliness, although our post-hoc analysis (i.e., including only children who had received 
DTPcv2) did indicate that timely vaccination coverage did improve among children in the 
HBR-only group compared with the control group, possibly identifying a group receiving 
better delivery of the intervention. A high proportion of healthcare providers did indicate 
they were not supportive of providing new home-based records to children, which could 
have factored into the modest effects of both interventions. The reminder sticker strategy 
may be a consideration if packaged with other interventions designed to improve parents’ 
knowledge and demand for vaccination, and in the context of better provider acceptance of 
the strategy or delivery mechanism.
Our results differ from the two HBR-based sticker reminder studies conducted in Pakistan 
that reported a positive effect of the intervention on completion of the DTPcv series [6,7]. A 
number of study characteristic differences may explain why our results differ from the 
studies in Pakistan. Specifically, our study was longer (7 months versus 3 months); used 
healthcare providers to implement the interventions rather than trained study personnel in 
Pakistan; included more study sites (90 health centers versus 5 in Pakistan); had relatively 
high baseline coverage (final control group DTPcv3 coverage was 81% versus 55% in 
Pakistan); experienced a lag in intervention startup in many study sites, whereas no reported 
lag occurred for the Pakistan study. All of these factors may have contributed to our results 
showing a more modest impact of home-based records and stickers as vaccination visit 
reminders compared with the previous Pakistan studies. However, our study may reflect 
more realistic results, at least for the Indonesia setting, considering that we used a similar 
approach to how the Indonesia Ministry of Health typically rolls out such interventions. In a 
2018 Cochrane Collaboration review of 23 high-income country setting studies examining 
patient reminder or recall interventions for childhood vaccination, there was a pooled 
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improvement in vaccination coverage of 8% (pooled RR = 1.22) from reminders, although 
the reminder types were numerous (postcards, text messages, auto phone dialers, telephone 
calls and letters to patients) [2,11]. Three studies from low-income country settings were not 
excluded from the review, but the review authors noted an overall positive but relatively low 
effect of the reminders evaluated in these studies. Although a variety of differences can exist 
between high income and middle or low income country immunization programs, the 
variation in results across low to high income country settings indicate the need to generate 
more evidence on reminder intervention effectiveness in low and middle income country 
settings.
One factor that may explain why control group health facilities eventually achieved the same 
level of coverage as the HBR + sticker intervention facilities is the use of a strategy in 
Indonesia known as sweeping. Although it is not meant to be a core strategy for vaccinating 
children, sweeping occurs every quarter and acts as a short vaccination campaign run by 
facility and community-based health workers to catch up all children <12 months of age who 
failed to return for vaccination at a health facility or outreach vaccination site. The 2012 
Indonesia immunization program review cited this strategy as unsustainable and urged the 
government to focus on investments in fixed and outreach-based vaccination as more 
sustainable strategies. It is possible that the sweeping activities succeeded in catching up 
those children who were missed, while in the HBR + sticker intervention group, those 
children who would have been vaccinated through sweeping instead ended up coming to the 
facility due to the effect of the sticker as a reminder of the next vaccination visit. Another 
possible explanation for the sticker having an effect on more timely vaccination but not on 
increased vaccination coverage is the timing of the sticker as a reminder, since it was 
provided at least 28 days prior to when the next visit would occur. The period between a 
reminder and the event for the reminder may dilute the reminder effect, particularly if the 
sticker-enhanced home-based record is not stored in a visible location in the household. It is 
possible that reminders provided closer to the potential visit, such as a phone-based text 
message to the parent one week prior to the visit or a mailed postcard received by the parent 
just prior to the visit, could have more effect.
The sticker and HBR strategy in our study was designed to encourage a change in behavior 
for the caregiver and appeared to be modestly successful in getting a significantly higher 
number of individuals to bring their children for more timely vaccinations than compared to 
control group individuals. However, the barrier addressed by these reminders is only one 
factor that determines why a child is incompletely vaccinated; other barriers also must be 
addressed for the reminder to work and effect change. Such health-sector–based examples 
can include vaccine stock-outs or lack of health workers when a parent returns with their 
child for a vaccination visit. Caregiver-based examples can include a parent being concerned 
about their child potentially developing a fever after vaccination. In particular, if parents 
have not been informed that post-vaccination fever can be a normal response, this reaction 
may result in their refusal to allow the child to receive any more vaccinations, whether or not 
they are reminded by the sticker and home-based record [12–14]. Indeed, an unpublished 
2014 immunization dropout study by UNICEF Indonesia reported that 70% of surveyed 
mothers of incompletely vaccinated children thought that fever after vaccination was not 
normal, 60% did not perceive any tangible benefits (i.e. immunity from disease, cost 
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savings, avoid death and disability) from vaccination of the child and only 34% indicated 
strong trust in their local health workers. These multiple maternal perceptions can lead to 
incomplete vaccination and would be challenging to solve through use of stickers and/or 
home-based records alone. A package of interventions which included the sticker alongside 
addressing interpersonal communications for immunization which would also address 
parental concerns about fever following vaccination and benefits of vaccination would be a 
useful strategy to build trust of the healthcare provider. Several previous reviews of 
strategies to improve community demand have identified the importance of the healthcare 
provider as a key and trusted source of immunization information, so establishing the 
provider – parent communication foundation first is critical for such reminder-recall 
strategies as the sticker to function well [12,15,16].
Although our study indicated that the use of stickers as reminders had only a modest effect 
on improving timeliness of vaccination, such an improvement can still be useful for 
decreasing vaccine-preventable disease (VPD) morbidity when translated into a population-
level effect. Several studies have shown that delayed vaccination is an important determinant 
of VPD morbidity in several high-income countries and may also contribute to disease 
outbreaks in other settings [17–20]. Vaccination delays can generally result in the most 
vulnerable group of children having more severe morbidity and higher mortality rates. 
Additionally, delays have economic impacts; a recent US-based study of delayed pertussis 
vaccination (which is included in the pentavalent vaccine used in Indonesia) indicated that 
pertussis vaccination at the exact recommended age in the United States could result in $1 
million in healthcare cost savings and prevention of 278 pertussis cases annually [21]. A 
future cost-effectiveness article is planned for this Indonesia study to better document the 
economic impact.
This study has a number of limitations. Although we tried to address exposure 
misclassification through per protocol analysis, we did identify a number of intervention 
group facilities that did not start the intervention during the expected timeline. We also did 
not have information at an individual level about whether a parent who attended an 
intervention facility actually received the specified reminder, so it is possible that even the 
per-protocol analysis may have underestimated the interventions’ effects. Within our per-
protocol analysis where multiple HBR + sticker facilities were re-classified as HBR-only, a 
majority of these facilities did initiate the intervention within 1–2 months after the 1-January 
start of the study; thus, children attending these facilities for their DTPcv2 dose would likely 
have been exposed to the intervention. However, any intervention effects within these 
facilities would have resulted in an under-estimate of the HBR + sticker effect even under 
per-protocol analysis, thus our observed results would be an under-estimate even under the 
per protocol analysis. The use of facility-based vaccination records to ascertain vaccination 
status meant that researchers were restricted to individual-level covariate data already 
routinely collected through this system; thus, in the per-protocol analysis, they could not 
control for other covariates commonly included in such analyses, such as maternal 
education, birth order of child, or parents’ income status and ethnicity. Additionally, children 
may have been misclassified with respect to the outcome (receipt of vaccination) as we only 
reviewed facility registers and did not also review home-based records; this misclassification 
would be non-differential due to our study design, and may have resulted in an 
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underestimate of the true strength of association between exposure and outcome. Our use of 
facility-based registers may have also missed children who tended to be more transient, i.e. 
moving from one facility to another for each vaccination visit and could be at higher risk of 
not having been recorded in the register; however any effect of this issue would be non-
differential due to the study design as well. Based on anecdotal reports from government 
health staff, the area where this study occurred had little health infrastructure beyond the 
public health facilities that were part of this study, hence it is considered that a low 
proportion of children moved between facilities in these areas. The healthcare provider 
interviews did reveal that the Indonesia MoH did not have standard protocols in place on 
how to remind parents about future vaccination visits, such that providers followed a variety 
of localized practices including creating their own written reminders. It may be possible that 
the introduction of the sticker intervention could have interfered with these existing provider 
practices, and as such, it would have been useful to have conducted baseline interviews with 
providers around these existing practices to better document, then control for such practices. 
Last, the control group coverage was about 10% higher (70% versus 81%) than had been 
assumed in the sample size calculations for seeing a desired effect size of >11%; the number 
of facilities would have to have been increased to 150 to have this same level of precision.
This study has several strengths. It was designed to closely mimic an effectiveness study and 
with scalability in mind by ensuring that health workers implemented the intervention rather 
than the study staff. The involvement of study staff members was further minimized by 
using a cascade-style training approach wherein district health teams oriented health workers 
to the interventions, as is typical for rollout of these types of interventions in Indonesia. 
Additionally, our per-protocol analysis of DTPcv3 coverage and timeliness and sensitivity 
analysis among only DTPcv2 recipients largely mirrored our ITT analysis.
Despite finding no effect on DTPcv3 coverage, further replication of this study with a 
modified intervention strategy and particularly in low-income countries with limited 
immunization program resources, would be useful for ensuring a full picture of the effects of 
these interventions. In any future research, including a follow-up survey of parents exposed 
to such reminder interventions, determining how they use home-based records in the home 
would be useful. The use of stickers and home-based records as reminders may also need to 
be included in an integrated healthcare provider–caregiver communications package 
designed to ensure parents receive adequate information on the benefits of vaccination, the 
likelihood of side effects and adverse events following immunization and how they should 
respond, when and where to return for future vaccination visits, and the use of an 
appointment reminder sticker on the home-based record, displayed in a visible location in 
the house.
5. Conclusion
Compared with standard practice, the combined use of the home-based record and an 
inexpensive appointment reminder sticker placed on the front of the home-based record led 
to modest improvement in the timeliness of DTPcv3 vaccination in our intervention group. 
Although substantial research is focused on assessing the effect of more expensive 
vaccination appointment reminder options (such as text or voice messages), additional 
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efforts are still needed to examine the effects of simple, easily deployable reminder options 
in resource-limited settings where logistical hurdles to deploying more sophisticated options 
exist. Further understanding the benefits and limits of such simple reminder options (like the 
reminder stickers) in other low- and middle-income country settings will provide valuable 
information to program managers considering the multiple options available for ensuring 
children continue to return and complete all recommended vaccinations.
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Fig. 1. 
CONSORT diagram for Indonesia vaccination reminder cluster randomized control trial, 
2015–2016. Definitions: sticker = reminder sticker placed on to the child’s home-based 
record.
Wallace et al. Page 15
Vaccine. Author manuscript; available in PMC 2020 October 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Intention-to-treat analysis of time to DTPcv3 vaccination by study group for parental 
reminder intervention cluster randomized, controlled trial in 90 health facilities, Indonesia 
2015–2016. DTPcv = Vaccine containing diphtheria, tetanus, pertussis, hepatitis B and 
Haemophilus influenzae type b antigens; DTPcv1 = 1st dose of DTPcv vaccine; DTPcv3 = 
3rd dose of DTPcv vaccine.
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Fig. 3. 
Per protocol analysis of time to DTPcv3 vaccination by study group for parental reminder 
intervention cluster randomized, controlled trial in 90 health facilities, Indonesia 2015–2016. 
DTPcv = Vaccine containing diphtheria, tetanus, pertussis, hepatitis B and Haemophilus 
influenzae type b antigens; DTPcv1 = 1st dose of DTPcv vaccine; DTPcv3 = 3rd dose of 
DTPcv vaccine.
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